Learn More
BACKGROUND The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer. METHODS HER2 status was tested in 33 mucinous carcinomas and 16 mucinous(More)
  • 1